Histocell’s R&D Department focuses on the development of new methods and technologies that are applied in regenerative medicine, using adult mesenchymal stem cells (AMSCs) and bioactive materials (scaffolds). Histocell R&D participates in several research programmes on bone regeneration, advanced wound healing, inflammatory diseases, neuroregeneration, ischaemia, lung therapy, etc. Moreover, Histocell offers a large portfolio of services, such as cell therapy services for clinical application, advanced molecular and cellular biology analysis services, biocompatibility testing and biological research services, among others.
Since its foundation in 2006, Histocell has developed an active R&D policy and currently has a wide experience in the development of R&D projects thanks to the execution of more than 40 R&D projects at national level, and 9 projects of the European Framework Programme for Research and Innovation (FPVII, Horizon 2020 and Horizon Europe). Histocell is committed to European collaborative projects as a way to increase its technical knowledge and skills. In the last 3 years, Histocell has submitted more than 20 proposals and its objective is to get involved in new projects within the current Horizon Europe programme (2021-2027).
Histocell’s R&D projects have been funded by:
- Ministerio de Educación y Ciencia
- Ministerio de Ciencia y Tecnología
- Ministerio de Ciencia e Innovación
- Departamento de Industria, Turismo y Comercio
- CDTI. Centro para el Desarrollo Industrial
- Fondo Europeo de Desarrollo Regional (FEDER)